Results 11 to 20 of about 12,890,416 (254)

Clinical assessment of immune-related adverse events

Therapeutic Advances in Medical Oncology, 2018
Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance.
Aaron Sosa, Esther Lopez Cadena, Cristina Simon Olive, Niki Karachaliou, Rafael Rosell   +4 more
doaj   +3 more sources

Metabolic syndrome and immune-related adverse events [PDF]

Cancer Immunology, Immunotherapy
Background Years into the immune checkpoint inhibitor (ICI) era, immune-related adverse events (irAE) remain largely unpredictable. Prior studies have examined irAE associations with weight and metabolic diseases, yielding mixed findings.
Katherine Lei, Meera J. Patel, Jialiang Liu, Rutu Aniruddha Rathod, Mitchell S. von Itzstein, Farjana J. Fattah, Hong Mu-Mosley, Jeffrey A. SoRelle, Jason Y. Park, Yang Xie, Amy E. Hughes, Heather Kitzman, David E. Gerber   +12 more
doaj   +2 more sources

Immune-related adverse events of immune checkpoint inhibitors: a review

Frontiers in Immunology, 2023
Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved.
Qinan Yin, Qinan Yin, Liuyun Wu, Liuyun Wu, Lizhu Han, Lizhu Han, Xingyue Zheng, Xingyue Zheng, Rongsheng Tong, Rongsheng Tong, Lian Li, Lian Li, Lan Bai, Lan Bai, Yuan Bian, Yuan Bian   +15 more
doaj   +3 more sources

Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis

Frontiers in Oncology
Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation 1.
Céline Eldani, Marie Kostine, Maxime Faure, Estibaliz Lazaro, Claire Rigothier, Jean Baptiste Hiriart, Bérénice Teulières, Florian Poullenot, Magalie Haissaguerre, Maeva Zysman, Rémi Veillon, Charlotte Vergnenegre, Nahema Issa, Charlotte Domblides, Sorilla Mary-Prey, Marie Beylot-Barry, Marie Beylot-Barry, Anne Pham-Ledard, Anne Pham-Ledard, Caroline Dutriaux, Guilhem Sole, Fanny Duval, Emilie Gerard   +22 more
doaj   +3 more sources

Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis

Frontiers in Oncology
AimThis study comprehensively assesses the incidence and profiles of treatment-related adverse events (trAEs) of immune checkpoint inhibitor (ICI)-based therapies across cancer at various sites.MethodsWe systematically searched the PubMed, Embase, and ...
Xin Shen, Jun Yang, Geng Qian, Mingyu Sheng, Yu Wang, Guohui Li, Jiaqing Yan   +6 more
doaj   +3 more sources

Correction: Metabolic syndrome and immune-related adverse events [PDF]

Cancer Immunology, Immunotherapy
Katherine Lei, Meera J. Patel, Jialiang Liu, Rutu Aniruddha Rathod, Mitchell S. von Itzstein, Farjana J. Fattah, Hong Mu-Mosley, Jeffrey A. SoRelle, Jason Y. Park, Yang Xie, Amy E. Hughes, Heather Kitzman, David E. Gerber   +12 more
doaj   +2 more sources

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events

Pharmaceuticals, 2023
Background: Immune-related cutaneous adverse events (ircAEs) are frequent and may reduce quality of life and consistent dosing. IL12/23 has been implicated in psoriasis, which is reminiscent of the psoriasiform/lichenoid ircAE phenotype.
Stephanie L. Gu, Tara Maier, Andrea P. Moy, Stephen Dusza, David M. Faleck, Neil J. Shah, Mario E. Lacouture   +6 more
doaj   +1 more source

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations

OncoImmunology, 2023
Immune-related adverse events (irAEs) are side effects of immune checkpoint inhibitor therapy (ICI). While common irAEs have been well characterized, there are more limited data on rare immune related adverse events (RirAEs) due to low incidence. Lack of
Benjamin C. Park, Sathya Narayanan, Alexander Gavralidis, Fei Ye, Run Fan, Ryan J. Sullivan, Genevieve Boland, Kerry L Reynolds, Justin M. Balko, Matteo S. Carlino, Georgina V. Long, Leyre Zubiri, Alexander M. Menzies, Douglas B. Johnson   +13 more
doaj   +1 more source

Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review

Frontiers in Oncology, 2021
BackgroundImmune Checkpoint Inhibitors (ICI) have been progressively used in cancer treatment and produced unique toxicity profiles. This systematic review aims to comprehend the patterns and occurrence of treatment-related adverse events (trAEs) based ...
Tao Ouyang, Tao Ouyang, Yanyan Cao, Yanyan Cao, Xuefeng Kan, Xuefeng Kan, Lei Chen, Lei Chen, Yanqiao Ren, Yanqiao Ren, Tao Sun, Tao Sun, Liangliang Yan, Liangliang Yan, Bin Xiong, Bin Xiong, Bin Liang, Bin Liang, Chuansheng Zheng, Chuansheng Zheng   +19 more
doaj   +1 more source

Rheumatological Adverse Events Following Immunotherapy for Cancer

Medicina, 2022
Background and Objectives: The occurrence of rheumatological side effects in a patient after receiving immunotherapy for cancer is becoming increasingly common. Oncologists often fail to diagnose and refer affected patients to rheumatologists. This paper
Ioana Cretu, Bogdan Cretu, Catalin Cirstoiu, Adrian Cursaru, Mihaela Milicescu, Mihai Bojinca, Ruxandra Ionescu   +6 more
doaj   +1 more source